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Edited by Peter Tontonoz and Laszlo NagyAbstract Energy homeostasis in mammals is achieved through
tight regulation of tissue-speciﬁc metabolic pathways that
become dysregulated in metabolic diseases including diabetes
and obesity. At the molecular level, main nutrient and hormonal
signaling pathways impinge on expression of genes encoding for
metabolic enzymes. Among the major components of this tran-
scriptional circuitry are the PGC-1a transcriptional complexes.
An important regulatory mechanism of this complex is through
acetylation and SIRT1-mediated lysine de-acetylation under
low nutrient conditions. Activation of SIRT1 can mimic several
metabolic aspects of calorie restriction that target selective nutri-
ent utilization and mitochondrial oxidative function to regulate
energy balance. Thus, understanding the PGC-1a and SIRT1
pathways might have important implications for comprehending
metabolic and age-associated diseases.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The initial studies in lower organisms found that the gene
SIR2 (silent information regulator; ortholog of mammalian
sirtuin SIRT1) potentially mediated the eﬀects of calorie
restriction on longevity [1], prompting diﬀerent groups to
investigate if SIRT1 had a role in metabolic function and lon-
gevity in mammals. Another active line of investigation was
the search for genes that control mammalian energy and nutri-
ent homeostasis. In this context, PGC-1a (peroxisome prolifer-
ator-activated receptor gamma-coactivator-1a) was identiﬁed
as transcriptional coactivator that could deﬁne tissue-speciﬁc
metabolic pathways in the adaptive response to environmental
and nutritional stimuli [2]. Work by our group and Finkel’s
group ﬁrst identiﬁed the functional interaction and deacetyla-
tion of PGC-1a and SIRT1. Furthermore, this interaction and
deacetylation could be regulated by energy ﬂuctuations and
nutrient levels, thus leading to direct transcriptional control
of metabolic enzymes and pathways [3,4]. We will discuss in
this section how these two proteins function mechanistically
in the context of controlling metabolic gene expression.*Corresponding author. Fax: +1 617 632 4779.
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doi:10.1016/j.febslet.2007.11.0341.1. PGC-1a functions as a transcriptional coactivator
PGC-1a belongs to a small family of transcriptional coacti-
vators, including PGC-1b and PRC which possess a common
function in mitochondrial physiology, in addition to control
over separate speciﬁc biological programs. PGC-1a was the
ﬁrst member identiﬁed as a cofactor for the nuclear hormone
receptor PPARc that is required for the adaptive thermogenic
response to lower temperatures [2]. Until mid 1990s most of
the regulation of gene expression and its biological implica-
tions were focused on transcription factors. During that time
the discovery of the ﬁrst transcriptional coactivators and core-
pressors for nuclear hormone receptors and other transcrip-
tions factors initiated a novel concept centered around the
control of speciﬁc genetic programs coordinated at the level
of the transcriptional cofactor. PGC-1a as a transcriptional
coactivator functions through direct physical interaction with
transcription factors directly bound to DNA promoter re-
gions. For example, LXXLL motifs in the PGC-1aN-terminus
interact with diﬀerent hormone nuclear receptors, including
PPARs, HNF4a, GR and ERRa. In addition, other parts of
the protein bind to other transcription factors such as NRF-
1 in the 200–400 region, MEF2C in the 400–565 region or
FoxO1 and YY1 in the RNA-processing C-terminal region
(Fig. 1). Importantly, the ability of PGC-1a to interact with
diﬀerent transcription factors allows for the coordinated
expression of gene sets in response to speciﬁc signals. However,
another important and interesting implication is the possibility
to activate gene expression in very speciﬁc contexts. As an
example, PPARc binding sites are present in UCP-1 and aP2
promoters, however PGC-1a only actives UCP-1, but not
aP2 [2]. So far, the molecular basis of this speciﬁcation is un-
known, but it might involve DNA-binding aﬃnities or facili-
tating interactions with other transcription factors or protein
complexes to promote availability to access the promoter.
The mechanisms through which PGC-1a activates gene
expression are poorly understood. Initial studies identiﬁed an
extremely powerful autonomous transcriptional activity at
the N-terminal region. This activation function correlates with
the ability of PGC-1a to dock on this domain two other coac-
tivators with acetyl transferase activity, SRC-1 and CBP/p300.
In addition, the C-terminal region contains an SR motif and
an RNA-binding domain. This region is required to induce
expression of certain endogenous genes and interacts with
proteins involved in RNA processing and the TRAP complex
involved in transcriptional initiation [5]. Moreover, PGC-1a
has been found in association with two additional diﬀerent
transcriptional complexes, the GCN5 and TIP60 acetyl
transferases complexes and many of their associated proteinblished by Elsevier B.V. All rights reserved.
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Fig. 1. Architecture of the PGC-1a transcriptional Coactivator. PGC-1a contains several functional domains that correlate with the interactions
with diﬀerent proteins and complexes. Additionally, PGC-1a contains speciﬁc phosphorylated, acetylated and methylated amino acids which can
modulate its activity. See text for further details.
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lysine residues and negatively regulates its transcriptional
activity, at least in part, through nuclear sublocalization.
How spatially and temporally all these complexes are assem-
bled to PGC-1a to control expression of genes is unknown.
A current model is that PGC-1a binds to speciﬁc transcription
factors at promoters, then, additional recruitment of p300 and
TRAP complexes would open the chromatin through histone
acetylation thereby allowing initiation of transcription through
RNA polII. Although GCN5 may acetylate histone H3 in this
complex, it would initially be refractory to acetylate PGC-1a.
The fact that the PGC-1a complex contains several proteins in-
volved in RNA elongation and processing also suggests that it
might move with the elongating phospho-RNA polII and par-
ticipate in fully maturation of the mRNAs [6]. To terminate
gene expression, GCN5 would acetylate PGC-1a resulting in
relocalization to repressive subnuclear foci where PGC-1a
has been shown to co-localize with the transcriptional repres-
sor RIP140 [6]. Conversely, SIRT1 activation will maintainFig. 2. Model for PGC-1a transcriptional gene expression activity. (1) PG
transferase activity that open and remodels chromatin to allow the transcriptio
would maintain deacetylated PGC-1a. (2) PGC-1a and its associated proteins
transcribe the mRNA. (3) After the mRNA processing, GCN5 would ace
subnuclear repressive foci. To initiate another cycle, SIRT1 would deacetyl
incorporated into protein complexes at promoter regions.PGC-1a in a deacetylated active form bound to the chromatin
and increasing rates of transcription (Fig. 2) [4,7].
However, this model is perhaps simplistic and does not take
into account the other PGC-1a modiﬁcations such as phos-
phorylation and methylation, as well as interaction with other
proteins including corepressors. Three kinases have been dem-
onstrated that directly phosphorylate PGC-1a. The stress-acti-
vated p38 MAP kinase phosphorylates PGC-1a at three
residues (Thr262; Ser265; Thr298) in the 200–400 repression
domain and correlates with a more active and stable protein
[8]. In addition to enhanced stability, the activity is further in-
creased due to the inability of the phospho-PGC-1a to bind the
p160 corepressor [9]. AMP kinase directly phosphorylates
PGC-1a at residues Thr177 and Ser538 resulting in a more ac-
tive protein [10]. Moreover, PGC-1a is phosphorylated by Akt/
PKB at Ser570 in the SR domain and leads to a more unstable
protein with lower activity [11]. Therefore, it seems that a ma-
jor mechanism by which phosphorylation functions is through
control of PGC-1a protein degradation and/or interactionC-1a is part of multiprotein complexes that contain histone acetyl
n factor to bind DNA. In the transcriptional initiation complex SIRT1
will move with RNA processing, elongation factors and RNA polII to
tylate PGC-1a localizing the whole complex to a RIP140 containing
ate PGC-1a freeing it from the repressive foci, allowing it to become
48 J.T. Rodgers et al. / FEBS Letters 582 (2008) 46–53with corepressor proteins. It is not known how these speciﬁc
phosphates control PGC-1a stability and the proteins involved
in this regulation. Furthermore, PGC-1a is a target of the pro-
tein arginine methyltransferase 1 (PRMT1) that also coacti-
vates nuclear hormone receptors. PRMT1 activates PGC-1a
transcriptional activity through methylation at three arginine
residues (Arg665, Arg667 and Arg669) at the C-terminus of
the protein [12]. It is conceivable that PGC-1a functions in
multiple protein complexes whose composition might depend
on the speciﬁc target gene as well as the combination of diﬀer-
ent signals that are on and/or oﬀ. For example, LRP130 (leu-
cine rich protein 130), a gene mutated in Leigh Syndrome
French Canadian, is part of the PGC-1a complex that regu-
lates a speciﬁc set of PGC-1a target genes in liver including
gluconeogenic genes and certain mitochondrial genes (Fig. 1)
[13]. Further identiﬁcation of the signals, speciﬁc protein com-
ponents and chemical modiﬁcations controlling these proteins
will certainly provide novel mechanistic information as to how
the whole PGC-1a metabolic biochemical machinery operates.
1.2. SIRT1 functions as a protein deacetylase
Sir2 was ﬁrst identiﬁed as a factor which regulated silencing
at the yeast mating type loci. Sir2 physically associates with
chromatin in regions of the genome that were transcriptionally
silent (mating type loci, telomere and centromeres) and also
functions in preventing recombination of rDNA repeats [1].
Sir2, as well as SIRT1, are both NAD+-dependent deacetylase
but neither used NAD+ as a redox acceptor. The NAD+
molecule is instead cleaved in the deacetylation reaction, trans-
ferring the acetyl group to the ribose sugar, thereby producing
O-acetyl-ADP-ribose and nicotinamide (Fig. 3). The released
nicotinamide ring can also function as an inhibitor of this reac-
tion [14,15]. As it relates to metabolism, the initial studies
searching for yeast aging genes in the caloric restriction nutri-
ent pathway identiﬁed Sir2. In worms and ﬂies it appears that
Sir2 is also involved in certain aspects of connecting calorie
restriction to lifespan [16,17].
Most of the biological functions attributed to Sir2 or SIRT1
depend on the enzymatic activity. So far, the SIRT1 molecular


































Fig. 3. Regulation of SIRT1 enzymatic activity. SIRT1 catalyzes a
NAD+-dependent protein deacetylase activity. This biochemical reac-
tion is regulated by diﬀerent metabolic inputs as well as several
polyphenols. Moreover, several metabolic pathways including NAD+
de novo biosynthesis from tryptophan and increasing the NAD+
salvage pathway inﬂuence SIRT1 enzymatic activity.gene expression. In some cases, SIRT1 represses transcription
and it is present in histone deacetylases and polycomb protein
complexes [18]. SIRT1 speciﬁcally represses transcription fac-
tors such as PPARc [19] and p53 [20]. The mechanism of
repression is not completely understood but involves physical
interaction with NCoR for PPARc and direct deacetylation
of p53 that decreases DNA-binding. In the case of FoxO pro-
teins, SIRT1 can be either positive or negative depending on
the type of target genes, but the mechanistic basis for this is
not completely understood [21]. SIRT1 acts positively on acti-
vation of other genes through direct deacetylation of PGC-1a
[4,7] and HIV Tat [22]. SIRT1 activates Tat-mediated tran-
scription of the HIV long terminal repeat. SIRT1 interacts
with PGC-1a in the 200–400 region and deacetylates PGC-
1a in at least 13 lysines in diﬀerent domains of the proteins
(Fig. 1). Mutation of these residues to arginine leads to a more
active PGC-1a allele [23].
Interestingly, it is also possible that SIRT1 functions outside
transcriptional control of gene expression. For example, Ace-
tylCoA synthetases are speciﬁcally deacetylated by SIRT1
increasing its enzymatic activity [24], these enzymes seem to
be very ancient substrates of Sir2 proteins that were originally
identiﬁed bacteria [25].
Several mechanisms of regulation for SIRT1 have been de-
scribed. First, nutrient deprivation (fasting or calorie restric-
tion) upregulates SIRT1 protein levels and seems to be
independent of its own mRNA induction [4]. In cultured hepa-
tocytes, pyruvate, a metabolite increased in fasting conditions,
induces SIRT1 protein levels aﬀecting translation of the pro-
tein. In skeletal muscle cells, resveratrol also increases SIRT1
protein levels [26]. How SIRT1 protein levels are regulated
and to what extent this is only at the translational level without
degradation control is currently unknown. Second, ﬂuctua-
tions in NAD+ or ratios of NAD+/NADH as well as nicotin-
amide concentrations will directly aﬀect SIRT1 enzymatic
activity. Thus, redox state of the cell controlled by the activi-
ties of diﬀerent metabolic pathways will change the ratio of
NAD+/NADH. In addition, changes in activities of enzymes
that control levels of these metabolites can aﬀect SIRT1 activ-
ity. For example, NAD+ biosynthesis from nicotinamide is cat-
alyzed in two reactions, one of the steps is controlled by the
enzyme Nicotinamide phosphoribosyltransferase (Nampt) also
known as PBEF or visfatin. Changes in the activity of this en-
zyme that occur in fasting conditions positively regulate SIRT1
activity. Finally, aside from these direct catalytic regulators, it
is possible that endogenous or natural compounds might act
similarly to resveratrol to increase SIRT1 activity (Fig. 3).2. Tissue-speciﬁc metabolic functions
2.1. Liver
Liver is a major buﬀering tissue that ensures nutrient homeo-
stasis in fed and fasting conditions. Metabolic adaptation to
fasting requires an important control at the transcriptional
level. PGC-1a is induced in the fasted liver to activate glucone-
ogenic and fatty acid oxidation genes. PGC-1a deﬁcient mice
lack this response and display hypoglycemia and hepatic stea-
tosis [27,28]. As part of the starvation response, signaling of
the fasting hormones glucagon and glucocorticoids increases
transcription of the PGC-1a gene. Glucagon signaling causes
translocation and de-phosphorylation of the transcriptional
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coactivates the CREB transcription factor which is present on
the PGC-1a and gluconeogenic promoters [29]. Once PGC-1a
is induced it will coactivate FoxO1 and HNF4a on the glu-
coneogenic genes such as PEPCK and G-6-Pase, increasing
transcription of these genes (Fig. 4). The entirety of PGC-1a
gluconeogenic activity requires these transcription factors, ge-
netic ablation of HNF4a and FoxO1 completely abolishes
PGC-1a’s ability to induce gluconeogenesis [30]. The counte-
regulatory eﬀects of insulin impact this network through acti-
vation of Akt which phosphorylates at least three components
of this signaling and transcriptional regulatory pathway. Akt
directly phosphorylates FoxO1 at three residues and results
in translocation to the cytoplasm forming a complex with
14-3-3 proteins [31]. Akt phosphorylates and activates the
Ser/Thr kinase SIK2. Activated SIK2 induces TORC2 phos-
phorylation that is degraded by the 26S proteasome in associ-
ation with COP1, a substrate receptor for an E3 ligase complex
that promoted TORC2 ubiquitination and degradation [29].
PGC-1a is directly phosphorylated by Akt and increases
PGC-1a protein degradation [11]. The eﬀects of PGC-1a in he-
patic lipid and mitochondrial metabolism are likely to function
through the nuclear hormone receptors PPARa, ERRa and
HNF4a. Moreover, lipin1a, a gene associated with lipodistro-
phy interacts with PGC-1a and positively controls fasted genes
of fatty acid oxidation [32].
Recently, our laboratory found that in parallel to this hor-
monal regulation there is a nutrient signaling that involves
SIRT1 and PGC-1a. SIRT1 is induced in the fasted liver and
interacts and deacetylates PGC-1a to activate gluconeogenic
and fatty acid oxidation genes. This nutrient signaling involves
increases in pyruvate and NAD+ levels resulting in elevated
SIRT1 protein amounts as well as enzymatic activity. Expres-
sion of a PGC-1a acetylation mutant – in which 13 lysines have
been mutated to arginines – maintains elevated expression of
gluconeogenic genes in the fed state [4,23]. These data imply
that PGC-1a undergoes cycles of acetylation and deacetylation
during the fed and fasted states that are dependent on SIRT1
activity. Furthermore, it also seems that the functions ofFig. 4. Hormonal and nutrient regulation of hepatic PGC-1a function. (1) H
catecholamines) through diﬀerent signaling cascades that target transcri
gluconeogenic enzymes. (2) Nutrient Regulation of PGC-1a through GCN5 ASIRT1 might go beyond the fed/fasted response. This is evi-
denced by the observation that independently of the fed status
of mice, hepatic SIRT1 controls systemic and hepatic choles-
terol levels likely dependent on increases in LXRa and PGC-
1b expression [23].
A current hypothesis poses that increased intracellular lipids
and ineﬃciency to couple b-oxidation of fatty acids to mito-
chondrial respiration in tissues such as liver and skeletal mus-
cle is a possible cause of insulin resistance and type 2 diabetes.
In the liver, this metabolic defect leads to non-alcoholic fatty
liver disease. Another main problem in diabetic patients is,
although they display hepatic insulin resistance, the constant
activation of lipogenesis also contributes to lipid accumulation
and metabolic dysfunction. Mice lacking PGC-1a develop fast-
ing hepatic steatosis probably due to lower rates of fatty acid
oxidation that might play a causative role to develop insulin
resistance [27,28]. Intriguingly, PGC-1a KO mice are more
insulin sensitive and resistant to high fat diet that could be re-
lated to hyperactivity. Alternatively, profound defects in fatty
acid oxidation might be compensated with increases in glucose
utilization to maintain energetic status. Moreover, lower rates
of fatty acid oxidation and OXPHOS activity can also lead to
decreases in rates of glucose synthesis that might improve glu-
cose tolerance and insulin sensitivity [33,34]. Notably, SIRT1
knock-down in the liver causes an increase of hepatic free fatty
acids which might also compromise insulin signaling [23]. Con-
sistent with that, it has been recently shown that SIRT1, sim-
ilar to FoxO1, increases insulin signaling. In the case of SIRT1
part of these eﬀects seems through inhibition of PTB1B [35].
One of the main contributors of hyperglycemia in diabetic
patients is increased hepatic glucose production in both fed
and fasted states. Knock-down of PGC-1a and SIRT1 in liver
lowers blood glucose in normal and db/db mice [36,23]. This
reduction correlates with lower hepatic glucose production
from pyruvate and increased glucose intolerance. Currently,
due to this PGC-1a/SIRT1 dual eﬀect in lipid and glucose
metabolism is diﬃcult to predict what it might be the ﬁnal out-
comes of the pharmacological activation of both proteins in
the liver in diabetes. It is possible that facilitation of fatty acidormones of the fed (insulin) and fasted (glucagon, glucocorticoids and
ptional complexes control expression of metabolic genes such as
cetyl transferase and SIRT1 deacetylase. See the text for further detail.
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dominant over glucose production. Thus, in normal insulin
sensitivity states, this hormone can eﬀectively suppress PGC-
1a activation of gluconeogenic genes. This would also be con-
sistent with the increases in insulin sensitivity and normal
blood glucose levels observed in mice treated with resveratrol
[26].2.2. Skeletal and cardiac muscle
Skeletal muscle represents a signiﬁcant percentage of the
total body mass and is energetically very active, especially in
conditions of increased physical activity induction of mito-
chondrial oxidative function become essential to adapt and
maintain the whole body energy balance. Several signaling
pathways are important to activate mitochondrial function in
skeletal muscle, for example Ca2+-regulated CAMKIV-calci-
neurin/NFAT and MEF2 axis, adrenergic and cholinergic sig-
naling and AMPK activation. These signaling/transcription
pathways can either induce and/or activate PGC-1a. Thus,
skeletal muscle-tissue speciﬁc PGC-1a transgenic mice display
higher mitochondrial content and a switch to oxidative type-1
ﬁbers [37]. On the contrary, skeletal muscle-speciﬁc PGC-1a
KO mice have deﬁcient expression of mitochondrial proteins
and develop myopathy that might be also related to its role
to regulate neuromuscular gene expression [38]. In the heart,
mitochondrial mass is also controlled by PGC-1a and is
important to maintain cardiac function in response to a variety
of stresses [39]. Similar to the liver, PGC-1a increases rates of
oxidation of fatty acids that are important in fasting and neo-
natal conditions.
Little is known about the function of SIRT1 in skeletal mus-
cle. In culture muscle cells SIRT1 seems to be involved in early
steps of diﬀerentiation by interfering with myogenic factors
[40]. Our group has found that in myotubes SIRT1 is required
for the switch from glucose to fatty acid utilization that occurs
in low nutrient conditions. Skeletal muscle cells trigger this
switch in a cell autonomous manner depending on glucose con-
centrations. One of the mechanisms by which SIRT1 exerts
these eﬀects is through PGC-1a deacetylation. Consistent with
SIRT1 activation, PGC-1a is deacetylated in fasting and in low
glucose conditions to induce a whole battery of genes involved
in mitochondrial fatty acid oxidation [7]. Intriguingly, resvera-
trol mimics the eﬀects of low glucose by targeting SIRT1 and
deacetylating PGC-1a. Mice treated with resveratrol have in-
creased mitochondrial function in several tissues and display
other metabolic changes that correlate with extension of life
span [41]. In addition, resveratrol induces a genetic program
in skeletal muscle that is consistent with higher energy expen-
diture that largely prevents increases in body weight under
high fat diet [26]. It would be also of interest to investigate if
the beneﬁcial eﬀects of PGC-1a in muscular degeneration are
also improved with SIRT1 activation.
In the context of type 2 diabetes, the role of PGC-1a and
SIRT1 in the liver seems to be more complex due to the posi-
tive eﬀects on both fatty acid oxidation and hepatic glucose
production (note that these two processes are activated in
nutrient deprivation conditions). However, the eﬀects in skele-
tal muscle of pharmacological activation of PGC-1a and
SIRT1 would be consistent with beneﬁcial results of both pro-
teins. Thus, increases in insulin sensitivity and energy expendi-
ture are observed in mice treated with resveratrol. It is alsoimportant to highlight the role that these two proteins might
play in exercise and physical activity. These energy-demanding
conditions activate AMPK that directly phosphorylates PGC-
1a at two residues (Thr177 and Ser53). Notably, increases of
target genes of AMPK such as GLUT4 and cytochrome c to-
tally depend on PGC-1a [10]. Full activation of PGC-1a in
skeletal muscle would allow eﬃcient b-oxidation of fatty acids
and coupling to mitochondrial oxidative phosphorylation. In
addition, PGC-1a maintains higher number of active mito-
chondria and OXPHOS proteins that are decreased in type 2
diabetes. As it relates to SIRT1 in skeletal muscle, transgenic
SIRT1 mice have increased physical activity and this also cor-
relates with higher insulin sensitivity [42] and increase in phys-
ical activity during calorie restriction requires SIRT1 KO [43].
Furthermore, increases in mitochondrial function and fatigue
resistance during exercise are also observed in mice treated
with resveratrol [26].
The physiological role of SIRT1 in the heart is unclear.
Transgenic mice with moderate expression of SIRT1 in heart
are more resistant to oxidative stress under pressure overload.
However, at high expression of SIRT1 mice develop cardiac
hypertrophy. Similar phenotypes have also been observed with
transgenic mice expressing PGC-1a in the heart [44]. Interest-
ingly, mice treated with resveratrol under high fat diet have
lower heart beat that could be related a decreases in locomotor
spontaneous activities [26].2.3. Brain
The brain constitutes perhaps the most vulnerable tissue to
oxidative stress. One of the strong phenotypes observed in
the PGC-1a KO are lesions in the striatal region of the brain
that controls movement. These mice are hyperactive and dis-
play progressive loss of striatal neurons that is reminiscent of
Huntington Disease [27]. Although is possible that some of this
phenotype might be partially due to a defective mitochondrial
gene expression and function, PGC-1a also activates genes
that encode enzymes involved in ROS detoxyﬁcation [45].
Thus, ROS induces PGC-1a expression and the lack of
PGC-1a correlates with a loss of protection against oxidative
stress damage. So far, the data of PGC-1a function in the
brain is consistent with a major role in neuroprotection. Inter-
estingly, SIRT1 plays a similar role in oxidative stress function
in combination with FoxO transcription factors [21]. More-
over, studies with mice treated with resveratrol and ectopic
expression of SIRT1 (that correlated with deacetylation of
PGC-1a) in the hippocampus further support the neuroprotec-
tive role of SIRT1 in Alzheimer’s disease and amyotrophic
lateral sclerosis [46]. Together, these studies suggest that
PGC-1a and SIRT1 might be potential targets to treat neuro-
degenerative diseases.
Another important physiological aspect related to the brain
is the role in energy balance through hypothalamic control of
food intake, energy expenditure and physical activity. Since the
hypothalamus controls food intake in fed and fasted condi-
tions through leptin, insulin and nutrient signaling pathways,
it is likely that PGC-1a and SIRT1 might play a role in mod-
ulating this response. However, PGC-1a KO mice, SIRT1
transgenic and resveratrol treated mice do not present any dif-
ference in food intake compared to control animals. Whether
other compensatory mechanisms are involved in keeping this
function is currently unknown.
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is energy expenditure. The observation that PGC-1a is in-
duced in conditions of elevated energy expenditure, such as
cold via adrenergic stimulation, suggests that it might control
part of this response. The conclusions about metabolic phe-
notypes in the PGC-1a and SIRT1 KOs should be taken with
caution and would be need to validate with tissue-speciﬁc
and inducible models. The total PGC-1a KO mice are
cold-intolerant indicating defective energy expenditure at
lower temperatures [27,28]. However, it seems to become
more complex when these mice are fed with high fat diet.
The fact that these mice are hyperactive with high spontane-
ous locomotor activity seems to make them resistant to in-
creases in body weight after high fat diet feeding. With
regard to the role of SIRT1 in energy balance, the studies
from the whole SIRT1 KO mice also provide little informa-
tion; these mice are smaller and present several abnormali-
ties. However, transgenic SIRT1 animals have higher
physical activity [42] and mice treated with resveratrol display
remarkably increase in energy expenditure [26]. In these two
mouse models, whether the eﬀects are due, at least in part, to
the SIRT1 function in the brain is unknown. Although more
data is needed from PGC-1a and SIRT1 tissue-speciﬁc KO
or transgenic mice, it appears that functions of these two
proteins correlate with increases in energy expenditure and
physical activity.2.4. Pancreas
Pancreatic b cells, together with a group of neurons in the
hypothalamus, constitute very sensitive cellular sensors for sys-
temic glucose levels. Small increases in glucose levels will stim-
ulate b cells that will secrete insulin to the blood. Little is
known about the role of PGC-1a in b cells, although initial
studies indicated that overexpression of PGC-1a correlated
with a decrease in insulin secretion [47]. However, further stud-
ies with PGC-1a KO mice should be performed to conﬁrm this
eﬀect. This is important given the relevance of mitochondrial
metabolism as well as ATP levels in insulin secretion. On the
other hand, it appears that SIRT1 promotes insulin secretion
through PPARc-mediated repression of the uncoupling pro-
tein UCP2 and altering intracellular concentrations of ATP
[48]. Similar to the skeletal muscle cells, b cells that lack SIRT1
do not fully sense ﬂuctuations of glucose and release normal
amounts of insulin. Given the protective eﬀects of both SIRT1
and PGC-1a in other cell types it would be interesting to know
whether these proteins might maintain b cell mass under oxida-
tive stress conditions.2.5. Adipose tissues
Among the ﬁrst studies in mammalian cells that provided a
metabolic functional role for PGC-1a as well as SIRT1 came
from the two types of adipose tissues; PGC-1a in brown adi-
pose tissue [2] and SIRT1 in white adipose tissue [19]. Cold
is a potent activator of brown adipose tissue thermogenic func-
tion that maintains body’s temperature. PGC-1a is strongly in-
duced in this situation and lack of PGC-1a correlates with
impaired cold tolerance. In addition, cultured brown adipo-
cytes lacking PGC-1a possess a deﬁcient thermogenic program
but are still able to diﬀerentiate into brown adipocytes [49].
This later function seems to be dependent on a new transcrip-
tional cofactor named PRDM16 [50].The thermogenic, similar to the gluconeogenic, response lar-
gely depends on the cAMP pathway and PGC-1a controls a
large set of the genes regulated by this pathway [49]. In addi-
tion, the lack of the three b-adrenoreceptors also produces cold
intolerance, supporting the necessity of this pathway to main-
tain corporal temperature. Thermogenic capacity in brown
adipose tissue depends on a high number of mitochondria with
uncoupling respiration that leads to heat production. This pro-
cess depends on a very abundant mitochondrial protein termed
UCP-1 which is exclusively expressed in brown adipocytes.
Expression of this protein entirely depends on b-adrenergic
stimulation and mice deﬁcient in UCP-1, similar to PGC-1a
and b-adrenoreceptors, are also cold intolerant.
In white adipose tissue PGC-1a is expressed at much lower
levels, however in situations of remodeling or activation by
b-agonists PGC-1a as well as its mitochondrial target genes
are increased. Ectopic expression of PGC-1a in white adipo-
cytes induces a thermogenic program strongly resembling that
of brown adipocytes. Another metabolic target of PGC-1a in
white adipocytes is glycerol kinase that might promote a futile
cycle of triglyceride hydrolysis and fatty acid reesteriﬁcation
[51], especially in combination with lipolytic activators such
as catecholamines.
SIRT1 is activated by low nutrient conditions in white adi-
pose tissue and induces systemic fatty acid mobilization. Sim-
ilar to pancreatic b cells it appears that the mechanism by
which SIRT1 induces lipolysis and prevent triglyceride accu-
mulation in white adipocytes is through repression of PPARc.
The mechanism involves SIRT1-dependent recruitment of the
transcriptional corepressor NCoR on PPARc targets such as
the abundant aP2 fat-selective gene. Furthermore, similar to
skeletal muscle cells, SIRT1 also interferes with the ability of
white adipocytes to fully diﬀerentiate, most likely by suppress-
ing PPARc function [19]. However, how SIRT1 controls the
adipocyte lipolytic action and whether PPARc is involved is
unknown. Recent transgenic mice in which SIRT1 is overex-
pressed in diﬀerent tissues including white adipose tissue dis-
play some of the metabolic features of caloric restricted mice
such as lower body weight, reduction in glucose and insulin
and increased glucose tolerance [42]. The role of SIRT1 in
brown adipose tissue and thermogenic function has not been
explored. Emerging genomic studies suggest a common cell
precursor between brown adipocytes and myotubes that coin-
cides with SIRT1 ability to block myogenesis and promote
brown adipocyte diﬀerentiation with increased mitochondrial
biogenesis [52]. In fact, other genomic studies have correlated
expression of SIRT1 with increases in mitochondrial genes that
is fully consistent with our own ﬁnding [7]. Along the same
lines, mice treated with resveratrol show higher PGC-1a
deacetylation in brown fat and expression of thermogenic
genes including UCP-1 [26]. However, future studies will need
to address SIRT1 function in this tissue and the possibility that
SIRT1 activators might be used to treat metabolic diseases by
increasing uncoupled respiration in brown adipose tissue. In
light of some new ﬁndings, the possibility of therapeutically
targeting brown fat thermogenic activities in humans might
take a new twist. It has been thought for a long time that
brown adipose tissue depots were only important in humans
at birth but not in adults, however, recent observations with
PET (positron emission tomography) analysis seems to pro-
vide evidence that adult humans have active brown fat depots
localized in diﬀerent areas of the upper body [53].
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The abundance of human metabolic diseases gives prime
illustration of what occurs when energetic homeostatic path-
ways become dysregulated. An interesting approach to the
problem of these diseases seems to be the study of the beneﬁ-
cial health eﬀects of prolonged calorie restriction and a more
detailed analysis of tissue-speciﬁc metabolic pathways includ-
ing how they function and adapt in normal physiology. In this
context, we have concentrated on how the PGC-1a and SIRT1
pathways seem to largely function together to promote tissue-
speciﬁc metabolic adaptation to nutrient ﬂuctuations. It may
be of no coincidence that dysregulation of many PGC-1a/
SIRT1 targets occurs in, or is even causative to metabolic dis-
eases.
Nutrient signals impinge on the PGC-1a and SIRT1 to con-
trol expression of genes encoding for proteins that execute tis-
sue-speciﬁc metabolic functions in response to this signal. In
most cases, these proteins are metabolic enzymes or additional
regulators that will change metabolite ﬂuxes within the cell or
tissue as well as impact functions of other tissues. Although the
speciﬁc nutrient signals which the PGC-1a/SIRT1 pathways
respond to remain elusive, it seems very likely that a nutrient
signal that ﬂuctuates in normal physiology would serve to syn-
chronize the metabolic networks of the entire body. It is there-
fore very plausible that the metabolic dysregulation that occurs
in disease might be due to the inability of the body to couple
normal nutrient/hormonal ﬂuctuation to the appropriate met-
abolic response. It is important also to mention that by inves-
tigating and identifying other genes and signals that are
upstream or downstream of the PGC-1a and SIRT1 complex
might provide novel insights into the pathology of these dis-
eases.
Although we have concentrated in this review at the connec-
tion of the PGC-1a and SIRT1 pathways, other functions of
these proteins could be independent of each other. In this re-
gard, future studies of how PGC-1a acetylation functions
and what sites are speciﬁc for diﬀerent biological activities will
also help to understand the implications of this protein com-
plex in metabolic regulation. Furthermore, we also need to
take into consideration other members of the PGC-1 family,
for instance PGC-1b also targets mitochondrial genes and in-
duces mitochondrial biogenesis. In fact, knock-down of both
PGC-1a and PGC-1b results in a collapse in mitochondrial
gene expression [49]. Another issue not covered in this review
is the possible eﬀects of PGC-1a and SIRT1 in other metabolic
tissues or cells. For example, how it might these proteins con-
tribute to energy balance its function in the thyroid or in mac-
rophages that also have considerable metabolic importance.
A major defect in type 2 diabetes and obesity can be deﬁned
as a lack of metabolic stability in which the body, tissue and
cells are not responsive to normal nutrient or hormonal ﬂuctu-
ations. A clear example is insulin resistance in type 2 diabetes.
However, many pathways are also likely to be defective in
these complex diseases. For example, old animals do not re-
spond similarly to exercise as young, the blunted response of
of AMPK and PGC-1a in old mice could exacerbate any met-
abolic complications. In addition, dysregulation of glucose and
lipid metabolic pathways will completely change intracellular
and systemic metabolite levels which will also further compro-
mise the cells to respond to hormonal and nutrient signals
appropriately. Related to this problem, it seems that at the‘‘heart’’ of type 2 diabetes and obesity are inﬂammatory re-
sponses and chronic oxidative stress that leads to ROS produc-
tion that might additionally complicate the pathology of these
diseases. In this context, PGC-1a, SIRT1 and SIRT1 targets,
such as FoxO proteins [21] and p53, control ROS formation
and are important to maintain survival [20]. Notably, increases
in free radical production have been causatively associated
with insulin resistance.
As it relates to the human genetics, several SNPs have been
found in PGC-1a that in certain populations are associated
with the diﬀerent aspects of the metabolic syndrome including
diabetes, obesity and hypertension. Recently SNPs for SIRT1
have also been identiﬁed in humans that were associated with
energy expenditure [26]. Finally, further genetic and metabolic
studies in diﬀerent human populations with diﬀerent suscepti-
bilities to metabolic diseases will provide more information of
how these pathways might be therapeutically exploited to treat
these diseases.
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